Upload
Featured Recent Articles Topics Upload Login Sign Up

Search Results for 'biosimilars clinical'

biosimilars clinical published presentations and documents on DocSlides.

Application of Biosimilars in RA IN Clinical Practice:
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges.  . Introduction. Diff...
Biosimilars
Biosimilars
by lindy-dunigan
Knowledge Connect Slide Resource. This slide dec...
Biosimilars in emerging markets- regulatory and Commercial considerations
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Biosimilars in RA: A Blessing or a Curse?
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
Biosimilars & EU regulation
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
  What is the value of Real-World Evidence for Biosimilars?
  What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Biological Products: concepts, naming,
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
PhAMA Position on Biosimilar Medicines
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
1 Immunogenicity The key safety issue for biosimilars
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Acceptable changes in quality attributes of glycosylated bi
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Category 1: Defining Terms
Category 1: Defining Terms
by jasmine
Clue: . A biologic product with no clinically mean...
Understanding Biologics Biologics and Biosimilars
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Faculty Leonard H. Calabrese, DO
Faculty Leonard H. Calabrese, DO
by trish-goza
Professor of Medicine. Cleveland Clinic Lerner Co...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilars Guideline – a Summary of the Industry Comments
Biosimilars Guideline – a Summary of the Industry Comments
by marina-yarberry
M Bredenhann | Nycomed | 19.11.10. BIOSIMILAR...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by aaron
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilars and biologics –
Biosimilars and biologics –
by gelbero
What does personalisation . mean . for you?. Ian N...
PhAMA Position on Biosimilar Medicines Ms. Leah
PhAMA Position on Biosimilar Medicines Ms. Leah
by conchita-marotz
PhAMA Position on Biosimilar Medicines Ms. Leah Go...